Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β2-agonists

被引：0

作者：

Zhang, Shiyuan ^{[1
]}

Czira, Alexandrosz ^{[2
]}

Harley, Julia ^{[3
]}

Rothnie, Kieran J. ^{[2
]}

Lee, Lauren ^{[3
]}

Small, Mark ^{[3
]}

机构：

[1] GSK, R&D Global Med, Collegeville, PA 19426 USA

[2] GSK, R&D Global Med, Brentford, Middx, England

[3] Adelphi Real World, Bollington, Cheshire, England

来源：

NPJ PRIMARY CARE RESPIRATORY MEDICINE | 2025年 / 35卷 / 01期

关键词：

DOUBLE-BLIND; MAINTENANCE; FORMOTEROL;

D O I：

10.1038/s41533-024-00402-w

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Inhaled corticosteroids (ICS) plus long-acting beta 2-agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS/LABA as maintenance-only or MART are limited. This study characterized clinical, economic, and humanistic burdens of asthma in Canada, China, Europe, Japan, and the US, using data collected from patients and physicians via a cross-sectional survey (Asthma Disease Specific Programme). Patients were >= 18 years of age with physician-confirmed asthma and receiving fixed-dose ICS/LABA for >= 3 months. Mean physician-reported symptom-free days over the past 30 days ranged from 10.1-20.6 days, and 31.5-34.6% of ICS/LABA users self-reported not well-controlled asthma. SABA co-prescription was reported in 8.8-67.8% of patients. These findings highlight the continued disease burden among ICS/LABA users, with the high level of SABA co-prescription indicating potentially inappropriate prescribing of ICS/LABA as MART or detrimental reliance on SABA medication in addition to MART.

引用

页数：10

共 29 条

[1] (2023)
[2] Czira A., Et al., A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma, Respir. Med, 191, (2022)
[3] Papi A., Et al., Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial, Lancet Respir. Med, 1, pp. 23-31, (2013)
[4] Patel M., Et al., Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial, Lancet Respir. Med, 1, pp. 32-42, (2013)
[5] Noorduyn S.G., Et al., SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada), ERJ Open Res, 8, pp. 00140-02022, (2022)
[6] Guyton S., Jackson T., Asthma control and medication reliance among asthmatics in a general practice setting—a questionnaire based study, Cureus, 14, (2022)
[7] Kim C., Et al., Effectiveness of maintenance and reliever therapy using inhaled corticosteroid-formoterol in asthmatics, J. Allergy Clin. Immunol. Pract, 10, pp. 2638-2645.e2633, (2022)
[8] Allegra L., Et al., Real-life prospective study on asthma control in Italy: cross-sectional phase results, Respir. Med, 106, pp. 205-214, (2012)
[9] Hermosa J.L., Sanchez C.B., Rubio M.C., Minguez M.M., Walther J.L., Factors associated with the control of severe asthma, J. Asthma, 47, pp. 124-130, (2010)
[10] Davis J., Trudo F., Siddall J., Small M., Burden of asthma among patients adherent to ICS/LABA: A real-world study, J. Asthma, 56, pp. 332-340, (2019)

← 1 2 3 →